Sana Biotechnology (SANA) Competitors $3.66 +0.16 (+4.57%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SANA vs. FLGT, ALLO, SAGE, ORTX, XNCR, EWTX, APLS, ZLAB, XENE, and PTCTShould you be buying Sana Biotechnology stock or one of its competitors? The main competitors of Sana Biotechnology include Fulgent Genetics (FLGT), Allogene Therapeutics (ALLO), Sage Therapeutics (SAGE), Orchard Therapeutics (ORTX), Xencor (XNCR), Edgewise Therapeutics (EWTX), Apellis Pharmaceuticals (APLS), Zai Lab (ZLAB), Xenon Pharmaceuticals (XENE), and PTC Therapeutics (PTCT). These companies are all part of the "medical" sector. Sana Biotechnology vs. Fulgent Genetics Allogene Therapeutics Sage Therapeutics Orchard Therapeutics Xencor Edgewise Therapeutics Apellis Pharmaceuticals Zai Lab Xenon Pharmaceuticals PTC Therapeutics Sana Biotechnology (NASDAQ:SANA) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, community ranking, risk and valuation. Which has more risk and volatility, SANA or FLGT? Sana Biotechnology has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Which has higher valuation and earnings, SANA or FLGT? Fulgent Genetics has higher revenue and earnings than Sana Biotechnology. Fulgent Genetics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSana BiotechnologyN/AN/A-$283.26M-$1.15-3.18Fulgent Genetics$289.21M2.26-$167.82M-$5.48-3.94 Is SANA or FLGT more profitable? Sana Biotechnology has a net margin of 0.00% compared to Fulgent Genetics' net margin of -56.22%. Fulgent Genetics' return on equity of -2.75% beat Sana Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Sana BiotechnologyN/A -85.27% -46.73% Fulgent Genetics -56.22%-2.75%-2.53% Does the MarketBeat Community prefer SANA or FLGT? Fulgent Genetics received 229 more outperform votes than Sana Biotechnology when rated by MarketBeat users. Likewise, 60.70% of users gave Fulgent Genetics an outperform vote while only 55.56% of users gave Sana Biotechnology an outperform vote. CompanyUnderperformOutperformSana BiotechnologyOutperform Votes1555.56% Underperform Votes1244.44% Fulgent GeneticsOutperform Votes24460.70% Underperform Votes15839.30% Does the media refer more to SANA or FLGT? In the previous week, Fulgent Genetics had 3 more articles in the media than Sana Biotechnology. MarketBeat recorded 5 mentions for Fulgent Genetics and 2 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 0.20 beat Fulgent Genetics' score of 0.16 indicating that Sana Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fulgent Genetics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of SANA or FLGT? 88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are owned by institutional investors. 31.1% of Sana Biotechnology shares are owned by company insiders. Comparatively, 31.8% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate SANA or FLGT? Sana Biotechnology currently has a consensus price target of $14.25, indicating a potential upside of 289.34%. Fulgent Genetics has a consensus price target of $30.00, indicating a potential upside of 38.82%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, equities analysts plainly believe Sana Biotechnology is more favorable than Fulgent Genetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sana Biotechnology 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Fulgent Genetics 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryFulgent Genetics beats Sana Biotechnology on 9 of the 17 factors compared between the two stocks. Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Get Sana Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for SANA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SANA vs. The Competition Export to ExcelMetricSana BiotechnologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$814.24M$3.15B$5.32B$8.52BDividend YieldN/A1.77%5.07%4.13%P/E Ratio-3.1815.47127.5316.08Price / SalesN/A321.091,490.6892.20Price / CashN/A149.0539.5134.18Price / Book2.514.024.765.07Net Income-$283.26M-$42.25M$118.77M$225.46M7 Day Performance-2.66%1.81%-0.38%0.06%1 Month Performance-13.68%8.56%6.06%3.93%1 Year Performance18.45%35.10%38.14%32.50% Sana Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SANASana Biotechnology2.6444 of 5 stars$3.66+4.6%$14.25+289.3%+18.4%$778.63MN/A-3.18328FLGTFulgent Genetics4.119 of 5 stars$19.42+1.4%$30.00+54.5%-9.0%$588.43M$289.21M-3.541,184Upcoming EarningsShort Interest ↑News CoverageALLOAllogene Therapeutics3.0217 of 5 stars$2.44-3.9%$9.96+308.0%-3.9%$509.96M$65,000.00-1.52232Upcoming EarningsAnalyst ForecastNews CoverageSAGESage Therapeutics4.3322 of 5 stars$8.01+2.0%$13.76+71.8%-69.3%$482.06M$97.24M-1.08690Earnings ReportAnalyst ForecastAnalyst RevisionORTXOrchard TherapeuticsN/A$16.70flatN/AN/A$380.09M$22.66M-17.77166News CoverageXNCRXencor4.0946 of 5 stars$21.16flat$34.78+64.4%+21.7%$1.30B$133.62M-7.32280Upcoming EarningsEWTXEdgewise Therapeutics1.983 of 5 stars$34.98+1.0%$35.60+1.8%+427.1%$3.28BN/A-22.5760Short Interest ↓Positive NewsAPLSApellis Pharmaceuticals4.5135 of 5 stars$26.68-3.3%$65.41+145.2%-43.9%$3.24B$628.79M-9.74702Upcoming EarningsAnalyst UpgradeAnalyst RevisionZLABZai Lab3.097 of 5 stars$32.37-2.4%$52.50+62.2%+23.1%$3.22B$322.71M-10.582,175XENEXenon Pharmaceuticals3.4499 of 5 stars$41.73-0.3%$57.45+37.7%+33.5%$3.15B$9.43M-15.23251Options VolumeNews CoveragePositive NewsPTCTPTC Therapeutics2.9999 of 5 stars$40.75-1.6%$40.08-1.7%+119.3%$3.13B$937.82M-6.461,410Upcoming Earnings Related Companies and Tools Related Companies FLGT Competitors ALLO Competitors SAGE Competitors ORTX Competitors XNCR Competitors EWTX Competitors APLS Competitors ZLAB Competitors XENE Competitors PTCT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SANA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sana Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sana Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
